|Bid||26.31 x 1000|
|Ask||26.70 x 1100|
|Day's Range||25.04 - 27.00|
|52 Week Range||4.03 - 28.10|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
\- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - \- Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor -MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, presented results of studies evaluating gedatolisib (a pan-PI3K/mTOR inhibitor), inavolisib (a PI3K-α inhibitor), and navitoclax (a BCL inhibitor) in breast and ovarian patient tumors.
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.